Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.

By R. Troughton, C. Frampton, T. Yandle, Eric A Espine, M. Nicholls, A. Richards. The Lancet, 2000

1,434 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure (2002, neutral): “DCMP 203 (69) 29 (66) 15 (48) * 296 (65) CAD 90 (31) 15 (34) 16 (52) 156 ( 35 )”
Guidelines for the diagnosis and treatment of chronic heart failure. (2001, background): “There is also recent evidence that adjusting heart failure therapy in order to reduce natriuretic peptides levels in individual patients may improve outcome([83]).”
State of the art: Using natriuretic peptide levels in clinical practice (2008, background): “In a pilot study of 69 patients with HF and systolic LV dysfunction randomised to receive therapy guided by NP levels or standard care, NP-guided treatment reduced total cardiovascular events and delayed time to first event [84].”
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ (2008, neutral): “Natriuretic peptides may also be useful in assessing prognosis prior to hospital discharge and in monitoring the effectiveness of HF therapy.(61,62) .”